283 related articles for article (PubMed ID: 31709477)
41. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.
Gamboa-Cárdenas RV; Ugarte-Gil MF; Loreto M; Sacnun MP; Saurit V; Cardiel MH; Soriano ER; Pisoni C; Galarza-Maldonado CM; Rios C; Radominski SC; Castelar-Pinheiro GDR; Bianchi WA; Appenzeller S; da Silveira IG; de Freitas Zerbini CA; Caballero-Uribe CV; Rojas-Villarraga A; Guibert-Toledano M; Ballesteros F; Montufar R; Vázquez-Mellado J; Esquivel-Valerio J; De La Torre IG; Barile-Fabris LA; Palezuelos FI; Andrade-Ortega L; Monge P; Teijeiro R; Achurra-Castillo ÁF; Esteva Spinetti MH; Alarcón GS; Pons-Estel BA
Clin Rheumatol; 2019 Oct; 38(10):2737-2746. PubMed ID: 31161486
[TBL] [Abstract][Full Text] [Related]
42. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
Haugeberg G; Hansen IJ; Soldal DM; Sokka T
Arthritis Res Ther; 2015 Aug; 17(1):219. PubMed ID: 26290061
[TBL] [Abstract][Full Text] [Related]
43. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
[TBL] [Abstract][Full Text] [Related]
44. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
Lillegraven S; Prince FH; Shadick NA; Bykerk VP; Lu B; Frits ML; Iannaccone CK; Kvien TK; Haavardsholm EA; Weinblatt ME; Solomon DH
Ann Rheum Dis; 2012 May; 71(5):681-6. PubMed ID: 21994234
[TBL] [Abstract][Full Text] [Related]
45. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
Futó G; Somogyi A; Szekanecz Z
Clin Rheumatol; 2014 May; 33(5):623-9. PubMed ID: 24599677
[TBL] [Abstract][Full Text] [Related]
46. Similar levels of disease activity and remission rates in patients with psoriatic arthritis and rheumatoid arthritis-results from the Finnish quality register.
Weman L; Salo H; Kuusalo L; Huhtakangas J; Kärki J; Vähäsalo P; Backström M; Sokka-Isler T
Clin Rheumatol; 2024 Feb; 43(2):633-643. PubMed ID: 38153614
[TBL] [Abstract][Full Text] [Related]
47. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
48. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Smolen JS; Aletaha D; Gruben D; Zwillich SH; Krishnaswami S; Mebus C
Arthritis Rheumatol; 2017 Apr; 69(4):728-734. PubMed ID: 27907269
[TBL] [Abstract][Full Text] [Related]
49. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
50. The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.
Inanc N; Yilmaz-Oner S; Can M; Sokka T; Direskeneli H
J Rheumatol; 2014 Sep; 41(9):1755-60. PubMed ID: 25086073
[TBL] [Abstract][Full Text] [Related]
51. Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study.
Santos IA; Donizeti Ribeiro de Oliveira R; Couto Luna Almeida S; Vargas-Santos AB; Balbino Chaves Amorim R; Monteiro Gomides AP; de Albuquerque CP; Barros Bertolo M; Brandão Resende Guimarães MF; da Costa Pinto MR; Gomes Resende G; Dalva Neubarth Giorgi R; de Carvalho Saciloto N; Radominski SC; Borghi FM; Rossi Bonfiglioli K; Carrico da Silva H; de Fatima L da Cunha Sauma M; Alves Pereira I; Werner de Castro GR; Viegas Brenol C; Machado Xavier R; Maria Henrique Mota L; Louzada-Junior P; da Rocha Castelar-Pinheiro G
PLoS One; 2022; 17(9):e0273789. PubMed ID: 36174077
[TBL] [Abstract][Full Text] [Related]
52. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
[TBL] [Abstract][Full Text] [Related]
53. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
54. Chinese registry of rheumatoid arthritis: IV. Correlation and consistency of rheumatoid arthritis disease activity indices in China.
Song X; Wang YH; Li MT; Duan XW; Li HB; Zeng XF;
Chin Med J (Engl); 2021 Jun; 134(12):1465-1470. PubMed ID: 34134125
[TBL] [Abstract][Full Text] [Related]
55. Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target.
Legrand J; Kirchgesner T; Sokolova T; Vande Berg B; Durez P
Joint Bone Spine; 2019 Oct; 86(5):594-599. PubMed ID: 30928534
[TBL] [Abstract][Full Text] [Related]
56. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.
Vermeer M; Kuper HH; Bernelot Moens HJ; Hoekstra M; Posthumus MD; van Riel PL; van de Laar MA
Arthritis Res Ther; 2012 Nov; 14(6):R254. PubMed ID: 23176083
[TBL] [Abstract][Full Text] [Related]
57. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.
Steunebrink LM; Vonkeman HE; ten Klooster PM; Hoekstra M; van Riel PL; van de Laar MA
Clin Rheumatol; 2016 Mar; 35(3):609-15. PubMed ID: 26852313
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
Schoels M; Alasti F; Smolen JS; Aletaha D
Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
[TBL] [Abstract][Full Text] [Related]
59. Predictors of long-term clinical remission in rheumatoid arthritis.
Fornaro M; Cacciapaglia F; Lopalco G; Venerito V; Iannone F
Eur J Clin Invest; 2021 Feb; 51(2):e13363. PubMed ID: 32725883
[TBL] [Abstract][Full Text] [Related]
60. Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.
Nakajima A; Terayama K; Sonobe M; Akatsu Y; Saito J; Norimoto M; Taniguchi S; Kubota A; Aoki Y; Nakagawa K
Cureus; 2021 Nov; 13(11):e19759. PubMed ID: 34938634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
